DAX
±0,00
%
Gold
±0,00
%
BörsenNEWS.de
Home
Börse
Märkte
Trends
Aktien
Indizes
Rohstoffe
Crypto
Derivate
Analyse
Niedrigstes KGV
Beste Dividende
Marktkapitalisierung
Meistgehandelt
Beste Performance
Termine
Handelskalender
Verfallstage
Community
Foren Übersicht
Meistdiskutiert
Community
News
Aktien
Indizes
Rohstoffe
Fonds
Anleihen
Zertifikate
Optionsscheine
Devisen
Crypto
News
Schlagzeilen
Nachrichten
Community
Meldungen
DAX-News
Dow Jones-News
MDAX-News
Märkte
Aktien
Indizes
Rohstoffe
Devisen
Partner
Archiv
KI-Fragen
Suche
SMARTBROKER
+
Depot
Suche
BörsenNEWS.de
Home
Suche
Suche
Sofort finden was Sie suchen
Alles
News
News
EQS-News: Immunic to Host MS R&D Day and Participate in Investor Conferences in April
News
EQS-News: Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
News
EQS-News: Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
News
EQS-News: Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
News
EQS-News: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
News
EQS-News: Immunic to Participate in Investor and Scientific Conferences in March
News
EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
News
EQS-News: Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
News
EQS-News: Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential
News
EQS-News: Immunic to Participate in Investor and Scientific Conferences in November and December
News
EQS-News: Immunic to Host MS R&D Day and Participate in Investor Conferences in April
News
EQS-News: Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
News
EQS-News: Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
News
EQS-News: Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
News
EQS-News: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
News
EQS-News: Immunic to Participate in Investor and Scientific Conferences in March
News
EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
News
EQS-News: Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
News
EQS-News: Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential
News
EQS-News: Immunic to Participate in Investor and Scientific Conferences in November and December
Anmelden
Login
Neu hier?
Jetzt Registrieren
Passwort vergessen?
weiter